Familial predisposition to uterine leiomyoma: searching for genetic factors that increase the risk of leyomyoma development

Sogoyan, N.S.; Kuznetsova, Maria; Донников, А Е; Мишина, Н. Д.; Mikhailovskaya, G.V.; Shubina, Jekaterina; Zelensky, Dmitry V.; Mullabaeva, Svetlana; Adamyan, L.V.

doi:10.17116/repro20202605151

Cited by 3 publications

(2 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent research has succeeded in stemming the leiomyoma and found a multi‐factorial inheritance pattern, but leiomyoma is still a matter of debate by experts and poses tremendous challenges 9,10 . More than 100 gene abnormalities are identified in leiomyoma, in the genes for estrogen receptors, progesterone receptors, growth factors, prolactin receptors, extracellular matrix, and collagens 11–14 . Apart from surgical procedures, there are numerous hormonal drugs for leiomyoma.…”

Section: Introductionmentioning

confidence: 99%

“…9,10 More than 100 gene abnormalities are identified in leiomyoma, in the genes for estrogen receptors, progesterone receptors, growth factors, prolactin receptors, extracellular matrix, and collagens. [11][12][13][14] Apart from surgical procedures, there are numerous hormonal drugs for leiomyoma. One of the non-hormonal drugs suggested for us in leiomyoma is N-acetyl cysteine (NAC), but its use for this indication is poorly understood.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The effect of N‐acetyl cysteine on the volume of uterine leiomyoma: A randomized clinical trial

Aghaamoo

Zandbina

Saffarieh

et al. 2021

Intl J Gynecology & Obste

View full text Add to dashboard Cite

Objective To conduct a clinical trial to investigate the effect of N‐acetyl cysteine (NAC), a non‐hormonal drug, on the volume of leiomyoma, the most common benign tumor in women. Methods This study is a randomized clinical trial, which was performed in Semnan, Iran. Eligible women who were diagnosed with uterine leiomyoma using vaginal ultrasound were randomly assigned to receive NAC or placebo for 12 weeks. The change in the volume of Leiomyoma was considered to be the main variable in the efficacy evaluation. Reduction in the leiomyoma volume was calculated after intervention and data were entered in SPSS version 23. Results Fifty individuals were enrolled in our study. 25 women received NAC, while 25 women took placebo. The mean volume of leiomyoma in group A was 5.71 cm3 and in group B was 6.56 cm3. The mean rate of volume reduction in the A and B groups was 25.25 % and 1.08 %, respectively, which demonstrated a significant difference between the two groups (P < 0.004). Conclusion Although this trial recommends the use of NAC as a non‐hormonal drug in the treatment of leiomyoma of the uterus, the possibility of treatment failure in controlling abnormal uterine bleeding cannot be ignored. Nevertheless, we can say it is feasible and effective in the reduction of leiomyoma volume.

show abstract

Section: Introductionmentioning

confidence: 99%